{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:06:11Z","timestamp":1777601171458,"version":"3.51.4"},"reference-count":44,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"\n Objective<\/jats:title>\n To ascertain the clinical impact, prevalence and associated determinants of delayed treatment intensification, defined as delaying the escalation of treatment plans for individuals with type 2 diabetes mellitus who fail to attain ideal glycaemic control, at the University of Gondar Comprehensive Specialised Hospital in Northwest Ethiopia.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A mixed-methods study.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n University of Gondar Comprehensive Specialised Hospital.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n 420 patients with type 2 diabetes mellitus with poor glycaemic control after the index date were included in this study. A simple random sampling technique was employed to select the required sample size. Data were collected retrospectively and entered into EpiData V.4.6 and exported to Stata V.14.2 for analysis.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n Multivariable logistic regression was used to identify factors associated with delayed treatment intensification. A p value of 0.05 in the multivariable analysis was considered statistically significant. Qualitative data were collected through in-depth interviews with eight selected healthcare providers, and thematic analysis was undertaken to identify the underlying barriers to timely treatment intensification.<\/jats:p>\n <\/jats:sec>\n \n Primary outcome<\/jats:title>\n Delayed treatment intensification.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The prevalence of delayed treatment intensification was 51.4% (95% CI 46.6% to 56.2%), with a median delay of 14 months (IQR: 7.5\u201342 months) from the index date. Among those experiencing delayed treatment intensification, 43.1% developed new chronic diabetic complications, including retinopathy (18.1%), neuropathy (14.4%) and nephropathy (6.0%). Other complications (hypertension, stroke, heart failure and diabetic foot ulcer) accounted for 4.64% of the cases. Significant predictors of delayed treatment intensification included longer duration of diabetes (adjusted ORs (AOR) 1.68; 95%\u2009CI 1.13 to 2.5), presence of comorbidities (AOR 1.83; 95%\u2009CI 1.04 to 3.2) and use of cardioprotective medications (AOR 1.59; 95%\u2009CI: 1.04 to 2.43). The qualitative findings revealed additional barriers contributing to delayed treatment intensification, including financial limitations, insufficient patient awareness and non-adherence among patients. Additionally, healthcare provider-related factors, including professional fatigue and knowledge gaps, as well as health institution-related factors such as inadequate healthcare infrastructure.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study found a high prevalence of delayed treatment intensification (51.4%), associated with comorbidities, longer disease duration, low patient awareness, cardioprotective drug use and barriers related to the system and providers. To address these gaps, priorities should include strengthening patient education, scheduling regular reviews for high-risk patients and improving clinical decision support tools for timely treatment intensification. Enhancing healthcare infrastructure, such as medication supply and diagnostic services, and offering refresher training to reduce provider fatigue, are also crucial for improving the delivery of diabetes care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-105455","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:48:08Z","timestamp":1762264088000},"page":"e105455","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence, determinants and consequences of delayed treatment intensification among type 2 diabetes mellitus patients at the University of Gondar Comprehensive Specialised Hospital, Northwest Ethiopia, 2024: a mixed-methods study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9361-1033","authenticated-orcid":false,"given":"Desalegn Addis","family":"Mussie","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, Debre Tabor University, Debre Tabor, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tigabu Eskeziya","family":"Zerihun","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, Debre Tabor University, Debre Tabor, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3431-8187","authenticated-orcid":false,"given":"Abel Temeche","family":"Kassaw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, Debre Tabor University, Debre Tabor, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esileman Abdela","family":"Muche","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, University of Gondar, Gondar, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2025121002501226000_15.11.e105455.1","doi-asserted-by":"crossref","unstructured":"Roglic DG . WHO global report on diabetes: a summary. Geneva: Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention, World Health Organization. Int J Non-Commun Dis 2023;1\u20136. doi:10.4103\/2468-8827.184853","DOI":"10.4103\/2468-8827.184853"},{"key":"2025121002501226000_15.11.e105455.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"2025121002501226000_15.11.e105455.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.06.003"},{"key":"2025121002501226000_15.11.e105455.4","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0662"},{"key":"2025121002501226000_15.11.e105455.5","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S185614"},{"key":"2025121002501226000_15.11.e105455.6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s12325-018-0819-5","article-title":"Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review","volume":"35","author":"Okemah","year":"2018","journal-title":"Adv Ther"},{"key":"2025121002501226000_15.11.e105455.7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1471-2261-14-162","article-title":"Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up","volume":"14","author":"Bramlage","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"2025121002501226000_15.11.e105455.8","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0951-8"},{"key":"2025121002501226000_15.11.e105455.9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.diabres.2019.01.017","article-title":"Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region","volume":"149","author":"Jabbar","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2025121002501226000_15.11.e105455.10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/dom.15337","article-title":"Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: areal-world observational study","volume":"26","author":"Shabnam","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025121002501226000_15.11.e105455.11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12902-023-01515-y","article-title":"Glycemic control and associated factors among type 2 diabetes mellitus patients: a cross-sectional study of Azar cohort population","volume":"23","author":"Dinavari","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"2025121002501226000_15.11.e105455.12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2013.00037","article-title":"Beta cell dysfunction and insulin resistance","volume":"4","author":"Cerf","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025121002501226000_15.11.e105455.13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/26350106241279809","article-title":"Patient-perceived challenges to type 2 diabetes self-management in Sub Saharan Africa: a qualitative exploratory Study","volume":"50","author":"Desse","year":"2024","journal-title":"Sci Diabetes Self Manag Care"},{"key":"2025121002501226000_15.11.e105455.14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-015-0260-x","article-title":"Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes","volume":"14","author":"Paul","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2025121002501226000_15.11.e105455.15","first-page":"1","article-title":"Therapeutic inertia and its impact on treatment and diabetes outcomes: the ADA approach","volume":"23","author":"Eckel","year":"2020","journal-title":"AMD Annals"},{"key":"2025121002501226000_15.11.e105455.16","doi-asserted-by":"crossref","first-page":"15952","DOI":"10.1038\/s41598-023-42774-y","article-title":"Magnitude of poor glycemic control and its predictors among adult diabetic patients on ambulatory chronic care follow-up at jimma medical center, southwest ethiopia; a focus on therapeutic inertia; cross-sectional study","volume":"13","author":"Dubale","year":"2023","journal-title":"Sci Rep"},{"key":"2025121002501226000_15.11.e105455.17","unstructured":"Rao LS . Redesigning treatment strategies in type 2 diabetes by treatment intensification and patient education. Pittsburgh (PA), University of Pittsburgh, 2015 Available: https:\/\/d-scholarship-dev-2.library.pitt.edu"},{"key":"2025121002501226000_15.11.e105455.18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4314\/ahs.v24i1.23","article-title":"Glycemic control and its associated factors among adult diabetic patients in Southern Ethiopia: a cross-sectional study","volume":"24","author":"Abose","year":"2024","journal-title":"Afr Health Sci"},{"key":"2025121002501226000_15.11.e105455.19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13088"},{"key":"2025121002501226000_15.11.e105455.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2042018819844694","article-title":"Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia","volume":"10","author":"Khunti","year":"2019","journal-title":"Therapeutic Advances in Endocrinology"},{"key":"2025121002501226000_15.11.e105455.21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/dom.12683","article-title":"Treatment intensification for patients with type 2 diabetes and poor glycaemic control","volume":"18","author":"Fu","year":"2016","journal-title":"Diabetes Obesity Metabolism"},{"key":"2025121002501226000_15.11.e105455.22","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-9-19","article-title":"The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study","volume":"9","author":"Goodall","year":"2009","journal-title":"BMC Endocr Disord"},{"key":"2025121002501226000_15.11.e105455.23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/safp.v65i1.5656","article-title":"Factors influencing insulin initiation in primary care facilities in Cape Town, South Africa","volume":"65","author":"Mathose","year":"2023","journal-title":"S Afr Fam Pract"},{"key":"2025121002501226000_15.11.e105455.24","first-page":"108623","article-title":"Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes","volume":"172","author":"Ji","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2025121002501226000_15.11.e105455.25","first-page":"182","article-title":"Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review","volume":"59","author":"Almigbal","year":"2023","journal-title":"Med Bogota Colomb"},{"key":"2025121002501226000_15.11.e105455.26","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1300109"},{"key":"2025121002501226000_15.11.e105455.27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/healthcare10091673","article-title":"Time to Treatment Intensification to Reduce Diabetes-Related Complications: A Post Hoc Study","volume":"10","author":"Kaewbut","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2025121002501226000_15.11.e105455.28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1573399812666151016101622","article-title":"Chronic Complications of Diabetes Mellitus: A Mini Review","volume":"13","author":"Lotfy","year":"2017","journal-title":"Curr Diabetes Rev"},{"key":"2025121002501226000_15.11.e105455.29","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115101"},{"key":"2025121002501226000_15.11.e105455.30","doi-asserted-by":"crossref","unstructured":"Hosmer DW , Lemeshow S , Sturdivant RX . Applied logistic regression. 3rd edn. Hoboken (NJ): Wiley, 2013.","DOI":"10.1002\/9781118548387"},{"key":"2025121002501226000_15.11.e105455.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240531","article-title":"Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study","volume":"15","author":"Wan","year":"2020","journal-title":"PLoS ONE"},{"key":"2025121002501226000_15.11.e105455.32","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/0300060516663095","article-title":"Therapeutic inertia and intensified treatment in diabetes mellitus prescription patterns: A nationwide population-based study in Taiwan","volume":"44","author":"Huang","year":"2016","journal-title":"J Int Med Res"},{"key":"2025121002501226000_15.11.e105455.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(12)71534-3"},{"key":"2025121002501226000_15.11.e105455.34","first-page":"3","article-title":"An observational study of clinical inertia among patients with type 2 diabetes mellitus in a tertiary care hospital","volume":"16","author":"Kaewbut","year":"2020","journal-title":"Arch Med Sci"},{"key":"2025121002501226000_15.11.e105455.35","doi-asserted-by":"publisher","DOI":"10.2337\/ds19-0029"},{"key":"2025121002501226000_15.11.e105455.36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12325-019-01199-8","article-title":"Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States","volume":"37","author":"Ali","year":"2020","journal-title":"Adv Ther"},{"key":"2025121002501226000_15.11.e105455.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2025121002501226000_15.11.e105455.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"2025121002501226000_15.11.e105455.39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s13300-019-00745-5","article-title":"Clinical Inertia in Poorly Controlled Type 2 Diabetes Mellitus Patients with Obesity: An Observational Retrospective Study","volume":"11","author":"Romera","year":"2020","journal-title":"Diabetes Ther"},{"key":"2025121002501226000_15.11.e105455.40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2337\/ds22-0084","article-title":"Therapeutic Inertia and Delays in Insulin Intensification in Type 2 Diabetes: A Literature Review","volume":"36","author":"Gavin","year":"2023","journal-title":"Diabetes Spectr"},{"key":"2025121002501226000_15.11.e105455.41","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.03.06.dc05-2078"},{"key":"2025121002501226000_15.11.e105455.42","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000109023.64650.73"},{"key":"2025121002501226000_15.11.e105455.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2013.10.008"},{"key":"2025121002501226000_15.11.e105455.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-018-5485-7","article-title":"Oral health knowledge, attitudes and care practices of people with diabetes: a systematic review","volume":"18","author":"Poudel","year":"2018","journal-title":"BMC Public Health"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-105455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T10:50:20Z","timestamp":1765363820000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-105455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-105455"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-105455","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}